References
Strawn JR, Keck PE Jr, Caroff SN (2007) Neuroleptic malignant syndrome. Am J Psychiatry 164:870–876
Goni M, Jimenez M, Feijoo M (1985) Parkinsonism induced by phenytoin. Clin Neuropharmacol 8:383–384
Ertan S, Ulu MO, Hanimoglu H et al (2006) Phenytoin-induced parkinsonism. Singapore Med J 47:981–983
Shalev A, Hermesh H, Munitz H (1989) Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 50:18–25
Trollor JN, Chen X, Sachdev PS (2009) Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 23:477–492
Ishioka M, Yasui-Furukori N, Hashimoto K et al (2013) Neuroleptic malignant syndrome induced by lamotrigine. Clin Neuropharmacol 36:131–132
Yaari Y, Selzer ME, Pincus JH (1986) Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol 20:171–184
Harrison MB, Lyons GR, Landow ER (1993) Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 8:19–27
Mendez JS, Cotzias GC, Mena I et al (1975) Diphenylhydantoin. Blocking of levodopa effects. Arch Neurol 32:44–46
Shulman LM, Singer C, Weiner WJ (1996) Phenytoin-induced focal chorea. Mov Disord 11:111–114
Stein MH, Sorscher M, Caroff SN (2006) Neuroleptic malignant syndrome induced by metoclopramide in an infant with Freeman-Sheldon syndrome. Anesth Analg 103:786–787
Shin HW, Chung SJ (2012) Drug-induced parkinsonism. J Clin Neurol 8:15–21
Conflict of interest
There is no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shin, HW., Youn, Y.C. Neuroleptic malignant syndrome induced by phenytoin in a patient with drug-induced Parkinsonism. Neurol Sci 35, 1641–1643 (2014). https://doi.org/10.1007/s10072-014-1826-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-014-1826-1